IRIDEX Earnings Call Transcripts
Fiscal Year 2025
-
Revenue grew 8% to $52.7M in 2025 with strong Q4 growth and positive adjusted EBITDA. Cost reductions and operational streamlining led to positive cash flow, while 2026 guidance projects 1–5% growth excluding Middle East sales.
-
The company is leveraging innovative laser technologies and strong clinical data to expand in both retina and glaucoma markets, with a focus on operational efficiency and margin improvement. Recent cost reductions, product launches, and a robust replacement cycle support a positive financial outlook.
-
Third quarter revenue grew 8% year-over-year to $12.5 million, with improved Adjusted EBITDA and reduced operating expenses. Gross margin was impacted by a one-time inventory write-down, but underlying profitability and cash flow trends remain positive.
-
Q2 2025 saw 7% year-over-year and 14% sequential revenue growth, reduced operating expenses by 28%, and positive adjusted EBITDA. Strong Pascal system sales drove retina segment growth, while cost controls and operational efficiencies improved financial health.
-
Revenue grew to $11.9M in Q1 2025, with positive adjusted EBITDA and improved gross margin. Cost reductions and a $10M investment strengthened the balance sheet, while growth in glaucoma products offset a slight retina revenue decline.
-
Recent cost reductions have led to positive adjusted EBITDA and improved cash flow, with continued revenue growth in both retina and glaucoma segments. A $10 million strategic investment from Novel Inspiration supports operational improvements, potential acquisitions, and a focus on long-term value creation.
Fiscal Year 2024
-
Q4 2024 saw revenue growth, improved gross margin, and positive adjusted EBITDA, driven by cost reductions and a strategic $10M investment from Novel Innovations. Glaucoma product sales rose, while retina sales dipped slightly. Industry M&A and LCD changes shape a positive 2025 outlook.
-
Leadership transition and cost-cutting have accelerated the strategic review, with Q4 expected to be EBITDA positive. Q3 revenue declined 10% year-over-year, but glaucoma product sales grew and regulatory changes are set to boost future adoption.
-
Q2 2024 revenue was $12.6M, up 7% sequentially, with recovery in both retina and glaucoma segments. Gross margin declined to 40.7%, and net loss narrowed to $2.7M. Strategic review and recent $3.4M financing aim to support growth and a potential transaction this year.